Repligen (NASDAQ:RGEN) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Repligen (NASDAQ:RGEN) from a peer perform rating to an outperform rating in a research note released on Tuesday, MarketBeat.com reports. The firm currently has $160.00 price target on the biotechnology company’s stock.

A number of other analysts have also issued reports on RGEN. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Royal Bank of Canada upped their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. Evercore ISI started coverage on Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.25.

Repligen Trading Down 0.6 %

Shares of RGEN opened at $137.20 on Tuesday. The company has a market cap of $7.70 billion, a P/E ratio of -269.02, a P/E/G ratio of 4.54 and a beta of 1.27. Repligen has a twelve month low of $102.97 and a twelve month high of $182.52. The company’s fifty day simple moving average is $138.22 and its 200-day simple moving average is $145.83. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million for the quarter, compared to analysts’ expectations of $163.65 million. During the same quarter in the prior year, the firm posted $0.28 earnings per share. The company’s quarterly revenue was up 10.4% on a year-over-year basis. As a group, analysts expect that Repligen will post 1.72 EPS for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of large investors have recently modified their holdings of the business. Rice Hall James & Associates LLC boosted its stake in Repligen by 26.4% in the 1st quarter. Rice Hall James & Associates LLC now owns 19,449 shares of the biotechnology company’s stock worth $2,475,000 after purchasing an additional 4,058 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% during the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock worth $1,858,000 after buying an additional 100 shares during the period. Stephens Investment Management Group LLC lifted its stake in shares of Repligen by 0.5% during the first quarter. Stephens Investment Management Group LLC now owns 539,542 shares of the biotechnology company’s stock worth $68,651,000 after buying an additional 2,741 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Repligen by 7.6% during the first quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company’s stock valued at $79,574,000 after buying an additional 43,946 shares during the last quarter. Finally, Diversify Wealth Management LLC raised its stake in Repligen by 11.2% in the 1st quarter. Diversify Wealth Management LLC now owns 3,717 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 375 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.